



#### Virtual vs. Reality: External Validation of COVID-19 Classifiers using XCAT Phantoms for Chest Computed Tomography

Fakrul Islam Tushar, Ehsan Abadi, Saman Sotoudeh-Paima, Rafael B.Fricks, Maciej A. Mazurowski, W. Paul Segars, Ehsan Samei, Joseph Y. Lo

Center for Virtual Imaging Trials, Carl E. Ravin Advanced Imaging Laboratories,

Dept. of Radiology, Duke University School of Medicine;

Dept. of Electrical & Computer Engineering, Pratt School of Engineering, Duke University.

SPIE Medical Imaging, Session #4 (COVID-19), paper #12033-9, Feb 21, 2022.














#### Infection statistics world-wide

# Effectively determine lung involvement

### Overview | COVID-19






Associated to COVID-19, Machine-learning, and Deep-learning.

### **Overview** Concerns





Near perfect diagnostic performance

disease appearance.



# Investigating variability of diagnostic performance based on disease appearance and imaging properties.

## — Challenging in real clinical setup

 Health concerns-Ionizing radiation






### **Overview** | Probable Solution



### **Probable solution** - Virtual Imaging Trials (VITs)




 — Virtual imaging trial (VIT) is a process of simulating imaging evaluations with varying factors such as computational human phantoms (CPs), imaging scanner systems, and virtual readers.

—AI model belongs in the virtual reader category.

### Method | Study Design




- Open-Source clinical data for model development.
- Generating Simulated CT scans utilizing VITs platform.
- Clinical Vs . Virtual performance analysis.






#### 12,000+ open-source clinical CT scans from 6,847 patients.




**U-10** Dataset

### Method | Model Development










E. Abadi, W. Paul Segars, H. Chalian, and E. Samei, "Virtual Imaging Trials for Coronavirus Disease (COVID-19)," AJR Am J Roentgenol, vol. 216, no. 2, pp. 362-368, Feb 2021, doi: 10.2214/AJR.20.23429.



#### Ground Truth 4D XCAT COVID-19 phantoms




E. Abadi et al. (2021).



4D **XCAT phantom** developed at Duke University

#### **Simulated CT**

**Simulated Xray** 



E. Abadi et al. (2021).




| Dose Level<br>(mAs) | Number of Volume |        |  |  |  |
|---------------------|------------------|--------|--|--|--|
|                     | COVID-19         | Normal |  |  |  |
| 5.7                 | 50               | 40     |  |  |  |
| 28.5                | 50               | 40     |  |  |  |
| 57                  | 50               | 40     |  |  |  |
| Total               | 150              | 120    |  |  |  |

### Method | Clinical Vs Virtual Data



|               | Clas     | Class Type |          | Label Level | Same CT scan |               |
|---------------|----------|------------|----------|-------------|--------------|---------------|
|               | COVID-19 | COVID-19   | Patient- | Slice-level | Pixel-       | with multiple |
| Datasets      | positive | negative   | level    |             | level        | dose levels   |
| MIDRIC-RICORD |          |            |          |             |              |               |


### Method |Inclusion and Exclusion



(i)i

### Method | Inference








| Test<br>(COVID+/-)<br>Training (COVID+/-) | MIDRIC-<br>RICORD<br>*(33/25) | MosMed<br>(174/52) | BIMCV-V2<br>(470/823) | U-10-Dataset<br>(1159/1201) | Duke-CVIT-<br>CT<br>(150/120) |
|---|-------------------------------|--------------------|-----------------------|-----------------------------|-------------------------------|
| MIDRIC-RICORD (90/72)                     | <b>0.69</b>                   | 0.66               | 0.54                  | 0.54                        | 0.57                          |
|   | [0.55,0.84]                   | [0.58,0.74]        | [0.51 <i>,</i> 57]    | [0.52-0.57]                 | [0.50,0.64]                   |
| MosMed (512/152)                          | 0.76                          | <b>0.87</b>        | 0.63                  | 0.68                        | 0.69                          |
|   | [0.64,0.88]                   | [0.81,0.92]        | [0.60,0.66]           | [0.66,0.70]                 | [0.63,0.76]                   |
| BIMCV-V2 (1421/2077)                      | 0.64                          | 0.58               | <b>0.77</b>           | 0.68                        | 0.68                          |
|   | [0.49,0.78]                   | [0.50,0.67]        | [0.74,0.79]           | [0.66,0.70]                 | [0.62,0.75]                   |
| U-10-Dataset                              | 0.74                          | 0.73               | 0.73                  | <b>0.85</b>                 | 0.79                          |
| (3926/3768)                               | [0.61,0.87]                   | [0.66,0.80]        | [0.70,0.76]           | [0.84,0.86]                 | [0.73,0.84]                   |




### Performance dropped due to domain-shift, simulated data consistent with multiple clinical test set.




### **Results** | Dose-level Analysis



# No dose dependence for all models tested on simulated data



### **Results** | COVID-19 Infection Size




(iii)


### **Results** | COVID-19 Infection Size



#### Infection volume strongly affects performances across all models and doses



Model U-DATA-10



### Conclusion



- Performance dropped due to domain-shift, simulated data consistent with multiple clinical test set.
- No dose dependence for all models tested on simulated data.
- Infection volume strongly affects performances across all models and doses
- Virtual Imaging Trials make it possible to answer clinically relevant questions.

### *CVIT: A growing community...*





#### tushar.ece@duke.edu